Literature DB >> 11489978

Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice.

T Okazaki1, A Nakao, H Nakano, F Takahashi, K Takahashi, O Shimozato, K Takeda, H Yagita, K Okumura.   

Abstract

Lung fibrosis is an important pulmonary disease with a high mortality rate, but its pathophysiological mechanism has not been fully clarified. Various types of cells have been implicated in the development of lung fibrosis, including T cells. However, the contribution of functional molecules expressed on T cells to the development of lung fibrosis remains largely unknown. In this study, we determined whether costimulation via CD28 on T cells was crucial for the development of lung fibrosis by intratracheally administering bleomycin into CD28-deficient mice. Compared with wild-type mice, the CD28-deficient mice showed markedly impaired lung fibrosis after injection with low doses of bleomycin, as judged by histological changes and hydroxyproline content in the lungs. In addition, bleomycin-induced T cell infiltration into the airways and production of several cytokines and chemokines including IL-5 were also impaired in the CD28-deficient mice. Furthermore, adoptive transfer of CD28-positive T cells from wild-type mice recovered the impaired bleomycin-induced lung fibrosis in CD28-deficient mice. These findings suggest that the CD28-mediated T cell costimulation plays a critical role in the development of lung fibrosis, possibly by regulating the production of cytokines and chemokines in the lung. Thus, manipulation of the CD28-mediated costimulation could be a potential therapeutic strategy for the prevention of lung fibrosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489978     DOI: 10.4049/jimmunol.167.4.1977

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

2.  Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury.

Authors:  Min He; Ni Cheng; Wei-wei Gao; Meng Zhang; Yue-yun Zhang; Richard D Ye; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 3.  Idiopathic pulmonary fibrosis and a role for autoimmunity.

Authors:  Gerard F Hoyne; Hannah Elliott; Steven E Mutsaers; Cecilia M Prêle
Journal:  Immunol Cell Biol       Date:  2017-03-30       Impact factor: 5.126

4.  Pulmonary vaccination as a novel treatment for lung fibrosis.

Authors:  Samuel L Collins; Yee Chan-Li; Robert W Hallowell; Jonathan D Powell; Maureen R Horton
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

5.  Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5.

Authors:  Yoko Tsukita; Tatsuma Okazaki; Satoru Ebihara; Riyo Komatsu; Mayumi Nihei; Makoto Kobayashi; Taizou Hirano; Hisatoshi Sugiura; Tsutomu Tamada; Nobuyuki Tanaka; Yasufumi Sato; Hideo Yagita; Masakazu Ichinose
Journal:  Oncoimmunology       Date:  2018-11-13       Impact factor: 8.110

6.  Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.

Authors:  Ji Hyung Kim; Hye Young Kim; Sanghee Kim; Jin-Haeng Chung; Weon Seo Park; Doo Hyun Chung
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

7.  Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice.

Authors:  Tatsuma Okazaki; Amy Ni; Peter Baluk; Oluwasheyi A Ayeni; Jennifer Kearley; Anthony J Coyle; Alison Humbles; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

8.  Complex regulation of pulmonary inflammation and fibrosis by CCL18.

Authors:  Kerill Pochetuhen; Irina G Luzina; Virginia Lockatell; Jung Choi; Nevins W Todd; Sergei P Atamas
Journal:  Am J Pathol       Date:  2007-06-14       Impact factor: 4.307

9.  Molecular and cellular mechanisms of pulmonary fibrosis.

Authors:  Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2012-07-23

10.  Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Fu Jun Li; Ranu Surolia; Huashi Li; Zheng Wang; Tejaswini Kulkarni; Gang Liu; Joao A de Andrade; Daniel J Kass; Victor J Thannickal; Steven R Duncan; Veena B Antony
Journal:  J Immunol       Date:  2017-07-28       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.